{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:50:18Z","timestamp":1790830218935,"version":"4.1.0"},"reference-count":29,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Close contacts of individuals with active pulmonary tuberculosis (TB) face an elevated risk of TB acquisition, necessitating systematic screening for latent TB infection and subsequent TB preventive treatment (TPT). Major TPT regimens require \u22653 months of drug exposure and demonstrate suboptimal safety profiles, significantly compromising treatment completion rates. Therefore, the development of shorter, safer chemoprophylaxis strategies represents a critical need in global TB control. Among close contacts, school-aged children and adolescents constitute the most vulnerable demographic subgroup, warranting prioritized intervention efforts.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n The primary objective of this study is to demonstrate noninferiority of an ultrashort, 1-month TPT regimen of isoniazid plus rifapentine, administered 3 times a week (1H\n 3<\/jats:sub>\n P\n 3<\/jats:sub>\n ) compared with the standard 3-month daily isoniazid plus rifampicin (3HR) regimen in preventing active TB, as measured by the 24-month cumulative incidence of active TB following randomization.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n An investigator-initiated, prospective, multicenter, open-label, noninferiority, cluster-randomized controlled clinical trial is being implemented under the auspices of the national TB control program in China. Close contacts of school pulmonary TB index cases, regardless of diagnostic type, are actively screened for symptoms using interferon-gamma release assays, chest imaging, and sputum molecular diagnostic testing to detect TB infection and exclude active TB. Eligible latent TB infection cases will be randomized in a 1:1 cluster ratio to receive either the standard 3HR regimen or the novel ultrashort 1H\n 3<\/jats:sub>\n P\n 3<\/jats:sub>\n regimen for TPT, with subsequent follow-up for up to 2 years to assess disease progression. The primary composite end point includes microbiologically confirmed TB (sputum culture or molecular diagnostic testing) or clinically diagnosed TB. With 80% power to detect noninferiority (20% margin), the study requires 1760 participants per arm, accounting for cluster design effects.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Recruitment started in September 2023. By the end of December 2025, a total of 2478 participants, comprising 627 index cases, had been enrolled, and recruitment is estimated to continue until September 2026. Data analysis will commence after the 2-year follow-up period, and the results are expected to be published by March 2029.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n This cluster randomized controlled trial aims to establish the noninferiority of a novel, ultrashort 1H\n 3<\/jats:sub>\n P\n 3<\/jats:sub>\n regimen compared to the standard 3-month 3HR regimen for preventing active TB in infected school contacts. If successful, this well-tolerated 1-month regimen could significantly improve treatment completion and optimize preventive therapy delivery in high-transmission congregate settings, thereby contributing substantively to global TB control efforts.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/89584","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:20:07Z","timestamp":1777292407000},"page":"e89584-e89584","source":"Crossref","is-referenced-by-count":1,"title":["A Novel Therapy With a One-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB\u2011YOUTH Study): Protocol for a Cluster Randomized Controlled Trial"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9741-5965","authenticated-orcid":false,"given":"Yixuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8443-2876","authenticated-orcid":false,"given":"Feiran","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2804-5291","authenticated-orcid":false,"given":"Yanfei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3580-3438","authenticated-orcid":false,"given":"Fudong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5180-5568","authenticated-orcid":false,"given":"Qingluan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4272-3202","authenticated-orcid":false,"given":"Yuying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3076-2650","authenticated-orcid":false,"given":"Xiaoling","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6756-3575","authenticated-orcid":false,"given":"Xing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9833-0416","authenticated-orcid":false,"given":"Jianfeng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8413-5177","authenticated-orcid":false,"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8514-1029","authenticated-orcid":false,"given":"Lingyun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7269-0205","authenticated-orcid":false,"given":"Jinlan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4931-3510","authenticated-orcid":false,"given":"Qiaoling","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1246-0747","authenticated-orcid":false,"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"R1","unstructured":"WHO consolidated guidelines on tuberculosis: module 1: prevention - tuberculosis preventive treatment, second edition. World Health Organization. 2024. URL: https:\/\/www.who.int\/publications\/i\/item\/9789240096196 [Accessed 07-05-2026]"},{"issue":"10228","key":"R2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0140-6736(20)30166-5","article-title":"The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis","volume":"395","author":"Martinez","journal-title":"Lancet"},{"issue":"12","key":"R3","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1038\/s41579-025-01201-x","article-title":"Mycobacterium tuberculosis biology, pathogenicity and interaction with the host","volume":"23","author":"Warner","journal-title":"Nat Rev Microbiol"},{"issue":"10481","key":"R4","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0140-6736(24)02479-6","article-title":"Tuberculosis","volume":"405","author":"Trajman","journal-title":"Lancet"},{"key":"R5","unstructured":"Implementing the end TB strategy: the essentials, 2022 update. World Health Organization. 2022. URL: https:\/\/www.who.int\/publications\/i\/item\/9789240065093 [Accessed 07-05-2026]"},{"issue":"12","key":"R6","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/aje\/kwx025","article-title":"Transmission of mycobacterium tuberculosis in households and the community: a systematic review and meta-analysis","volume":"185","author":"Martinez","journal-title":"Am J Epidemiol"},{"issue":"4","key":"R7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/infdis\/jiu138","article-title":"Integrating social contact and environmental data in evaluating tuberculosis transmission in a South African township","volume":"210","author":"Andrews","journal-title":"J Infect Dis"},{"issue":"1","key":"R8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S2352-4642(19)30337-2","article-title":"Adolescent tuberculosis","volume":"4","author":"Snow","journal-title":"Lancet Child Adolesc Health"},{"issue":"8","key":"R9","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S2213-2600(24)00083-3","article-title":"Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing studies","volume":"12","author":"Martinez","journal-title":"Lancet Respir Med"},{"issue":"5","key":"R10","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/cid\/ciy987","article-title":"High prevalence of active and latent tuberculosis in children and adolescents in Tibetan schools in India: the Zero TB Kids Initiative in Tibetan refugee children","volume":"69","author":"Dorjee","journal-title":"Clin Infect Dis"},{"issue":"1","key":"R11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-31419-x","article-title":"Acceptance of preventive therapy for latent tuberculosis infection in Chinese children and adolescents: a systematic review and meta-analysis","volume":"16","author":"Peng","journal-title":"Sci Rep"},{"issue":"1","key":"R12","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2025.2502010","article-title":"Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB)","volume":"14","author":"Ruan","journal-title":"Emerg Microbes Infect"},{"issue":"2","key":"R13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.46234\/ccdcw2021.009","article-title":"Guidelines for the prevention and control of tuberculosis in schools: recommendations from China CDC","volume":"3","author":"Xia","journal-title":"China CDC Wkly"},{"issue":"2","key":"R14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044143","article-title":"Characteristics and practices of school-based cluster randomised controlled trials for improving health outcomes in pupils in the UK: a systematic review protocol","volume":"11","author":"Parker","journal-title":"BMJ Open"},{"issue":"1","key":"R15","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01348-0","article-title":"Characteristics and practices of school-based cluster randomised controlled trials for improving health outcomes in pupils in the United Kingdom: a methodological systematic review","volume":"21","author":"Parker","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"R16","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1183\/13993003.00235-2016","article-title":"Annual risk of tuberculosis infection in rural China: a population-based prospective study","volume":"48","author":"Gao","journal-title":"Eur Respir J"},{"issue":"10","key":"R17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1473-3099(17)30402-4","article-title":"Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study","volume":"17","author":"Gao","journal-title":"Lancet Infect Dis"},{"key":"R18","unstructured":"Analysis plan: section 2: intraclass correlation. Rethinking Clinical Trials. URL: https:\/\/rethinkingclinicaltrials.org\/chapters\/design\/analysis-plan-top\/intraclass-correlation\/ [Accessed 07-05-2026]"},{"issue":"6","key":"R19","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1038\/s41591-025-03668-w","article-title":"SPIRIT 2025 statement: updated guideline for protocols of randomized trials","volume":"31","author":"Chan","journal-title":"Nat Med"},{"key":"R20","unstructured":"Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services. 2017. URL: https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf [Accessed 07-05-2026]"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1550-y","article-title":"Initiation and completion rates for latent tuberculosis infection treatment: a systematic review","volume":"16","author":"Sandgren","journal-title":"BMC Infect Dis"},{"issue":"5","key":"R22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa1714283","article-title":"Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults","volume":"379","author":"Menzies","journal-title":"N Engl J Med"},{"issue":"23","key":"R23","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","journal-title":"N Engl J Med"},{"issue":"1","key":"R24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365","author":"Martinson","journal-title":"N Engl J Med"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2024.100422","article-title":"The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India","volume":"31","author":"Bhargava","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"12","key":"R26","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens10121591","article-title":"The impact of tuberculosis on the well-being of adolescents and young adults","volume":"10","author":"Moscibrodzki","journal-title":"Pathogens"},{"issue":"8","key":"R27","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf452","article-title":"Epidemiological analysis of tuberculosis transmission, risk factors, and subclinical tuberculosis management in a high school outbreak, South Korea","volume":"12","author":"Choi","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"R28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.5588\/ijtld.18.0283","article-title":"Temporal trends in the prevalence of infection in South African adolescents","volume":"23","author":"Bunyasi","journal-title":"Int J Tuberc Lung Dis"},{"key":"R29","unstructured":"Towards a TB-free India, village by village. World Health Organization. 2024. URL: https:\/\/www.who.int\/india\/news-room\/feature-stories\/detail\/towards-a-tb-free-india--village-by-village [Accessed 07-05-2026]"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e89584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:24:37Z","timestamp":1785536677000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e89584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":29,"URL":"https:\/\/doi.org\/10.2196\/89584","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"v15i10228e89584"}}